The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.

A method comprising the steps of applying an adhesive composition to a substrate bone repair region. The adhesive composition comprises a porous, biocompatible, biodegradable, resorbable, non-toxic, and polymerizable composition. The substrate bone repair region comprises a bone structure, implant or device surface, or tooth surface. The adhesive composition is cured to provide a polymerized adhesive composition resulting in repairing or augmenting the substrate bone repair region. The adhesive composition may be mixed with a bone graft material before application. The adhesive composition may be additionally applied to a barrier membrane that is placed over the substrate bone repair region where the adhesive composition or combination of adhesive composition and bone graft material is applied.

The instant disclosure is directed to methods of treating articular or hyaline cartilage damage or injury using biocompatible electrospun polymer fibers. Methods are also directed to treating arthritis, particularly osteoarthritis or rheumatoid arthritis, using biocompatible electrospun polymer fibers. Such methods may involve placing a patch comprising at least one electrospun polymer fiber in physical communication with the damaged cartilage. In certain embodiments, the patch may comprise substantially parallel electrospun polymer fibers.

The present invention relates to: an amorphous of spherical embolisation hydrogel having a degradation time that can be precisely controlled in blood vessels; and a preparation method therefor.

This tissue-joining member comprises non-crosslinked fibrous collagen. A laminate body comprises: a support; a joining member that is layered on one surface of the support; and a first adhesive layer that is layered on said one surface of the support in a region on which the joining member is not layered. The method for using the joining member or the laminate body comprises: a heating step in which the joining member or the laminate body is heated to less than 60? C. and greater than body temperature after having being layered on the tissue; and a cooling step in which the heated joining member or laminate body is cooled to body temperature or lower. A treatment system comprises a heating unit and the joining member or the laminate body.

This invention relates to collagen biomaterials and methods for manufacturing collagen biomaterials. Method disclosed herein include steps of providing a suspension of insoluble collagen fibres, providing a layer deposition interface and applying an electric field across the suspension to cause electrophoretic deposition of the insoluble collagen fibres at the layer deposition interface. Biomaterials disclosed herein include a layer comprising an array of fibres of collagen, and a layered composite material comprising at least first and second fibrous layers each comprising an array of fibres of collagen, and a shape adapting layer sandwiched between the first and second fibrous layers. Biomaterials as described herein may be useful in a range of tissue engineering and other applications.

A sheet-like hemostatic material is provided with: an adhesive layer which serves as an affixing surface to a bleeding site and which is formed from at least poly--glutamic acid (-PGA); and a covering layer which is a sheet formed from at least one biodegradable material (covering material) other than -PGA, and which serves as an opposite surface to the affixing surface. At least one of the adhesive layer and the covering layer is a single sheet. If the adhesive layer is a single sheet, the adhesive layer should be a sponge-like sheet, and if the adhesive layer is a partial layer, the adhesive layer should be a sponge-like sheet or a nonporous layer. Alternatively, in another sheet-like hemostatic material, a sheet which is formed from at least poly--glutamic acid (-PGA) and to which at least one of a saccharide and collagen has been added is provided as the adhesive layer.

Biomaterials, implants made therefrom, methods of making the biomaterial and implants, methods of promoting bone or wound healing in a mammal by administering the biomaterial or implant to the mammal, and kits that include such biomaterials, implants, or components thereof. The biomaterials may be designed to exhibit osteogenic, osteoinductive, osteoconductive, and/or osteostimulative properties.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.